

Remarks

An Amendment Under 37 CFR §1.111 was transmitted to the Patent Office on September 3, 2003 in the subject application. Following the September 3 Amendment, claims 1, 8-13, 15, 16, and 19-57 are pending in the subject application and currently before the Examiner for consideration. By this Supplemental Amendment, Applicants have amended the subject specification at pages 6, 7, 20, 21, 23, and 24 to include the SEQ ID numbers for oligonucleotides of the invention and to correct minor typographical errors. Applicants respectfully submit that these amendments will require no further search or examination on the part of the Examiner and do not constitute new matter. Entry and consideration of the amendments presented herein is respectfully requested. Favorable consideration of the pending claims is respectfully requested.

In view of the foregoing remarks and amendments to the specification, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

RECEIVED
CENTRAL FAX CENTER

SEP 09 2003

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

OFFICIAL

DRP/s1

JASUSFT176XSupp-Amd.doc/DNB/s1